Silencing TUG1 promotes BC cell cycle progression through the upregulation of cell cycle protein D1 and cell cycle protein-dependent kinase 4 (CDK4) (Iliaki et al., 2021), natural active compounds combined with first-line chemotherapeutic agents are increasingly being studied. Here, CDK4 is linked to breast cancer.